Compare what each hip option can do

Try movement and simple aids first

Shorten your walk before giving it up. You'll add distance slowly when soreness eases.

Hold a cane on your other side. Use a higher seat if deep bending pinches.

For outer soreness, don't sleep on that hip. Cushion your knees to ease the pressure.

Water exercise puts less weight on your hip. It'll still keep the joint moving.

These changes won't prove the cause. They'll show which activities feel manageable.

Ask about medicine and clinic care

Some medicines may briefly ease soreness. They won't suit every heart, kidney, or stomach.

Review your risks with a doctor or pharmacist. Don't copy another person's medicine routine.

At QC Kinetix, concentrated platelet-rich plasma (PRP) means a medical provider spins your blood, saves the platelet-heavy part, and puts it into your hip without surgery.

Hip studies don't prove PRP beats salt water placed inside the joint. You'll ask about risks, cost, and follow-up.

Know when replacement may fit better

Hip replacement can help when severe arthritis limits daily life. It isn't the same as arthroscopy.

Replacement changes the worn joint surfaces. Arthroscopy uses small openings inside the joint.

Hip replacement alternatives are the non-surgical choices above. How long you've hurt doesn't decide when replacement fits.

Ask what your X-ray shows about joint wear. Then weigh your sleep, walking, and independence.

Sources

1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programmes, tai chi, cane use and oral NSAIDs across hand, hip and knee OA - but its strong recommendations for topical NSAIDs and for intra-articular glucocorticoid injection are specific to the KNEE, not the hip.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. OARSI 2019 designates arthritis education plus structured land-based exercise as CORE treatments for hip OA, and explicitly states that intra-articular corticosteroids, intra-articular hyaluronic acid and aquatic exercise - Level 1B/2 treatments for KNEE OA - were NOT recommended for individuals with hip or polyarticular OA. Oral and transdermal opioids are strongly not recommended (Level 5).

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

3. The 2026 Cochrane update of exercise for hip osteoarthritis (18 trials, 1368 participants) found that against attention control or placebo, exercise may have little to no effect on pain (MD -6.31 points on 0-100, 95% CI -12.98 to 0.35, low certainty) and may improve physical function only slightly; against no treatment or usual care it probably reduces pain slightly (MD -7.19, 95% CI -10.70 to -3.68, moderate certainty) but the review states these improvements are unlikely to be clinically meaningful. This is a weaker result than the equivalent knee evidence and it must not be overstated.

   Hall M, et al. — Exercise for osteoarthritis of the hip.. Cochrane Database of Systematic Reviews, 2026. DOI: 10.1002/14651858.CD007912.pub3.

4. The AAOS evidence-based clinical practice guideline on Management of Osteoarthritis of the Hip states verbatim: STRONG evidence supports intra-articular corticosteroids to improve function and reduce pain in the SHORT TERM; STRONG evidence does NOT support intra-articular hyaluronic acid, because it does not perform better than placebo for function, stiffness and pain; STRONG evidence supports physical therapy for mild to moderate symptoms; STRONG evidence supports NSAIDs for short-term pain and function; and MODERATE evidence does not support glucosamine sulfate.

   American Academy of Orthopaedic Surgeons — Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline.. AAOS, 2017.

5. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

6. FDA states verbatim that regenerative medicine products including stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosomes have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders affecting blood production.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA, 2026.

7. Pooled analysis of national joint registries (Australia and Finland, 215,676 hip replacements) put 25-year all-cause construct survival at 57.9% (95% CI 57.1-58.7); pooled case series gave 77.6% (95% CI 76.0-79.2). The authors conclude patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

   Evans JT, et al. — How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up.. The Lancet, 2019. DOI: 10.1016/S0140-6736(18)31665-9.

8. A population-based analysis of 63,158 total hip replacements found 10-year implant survival of 95.6% and 20-year survival of 85.0%, but the LIFETIME risk of revision rose sharply with younger age at surgery - about 5% for those operated after 70, up to 35% (95% CI 30.9-39.1) for men in their early 50s, with a median time to revision of 4.4 years in those operated before 60.

   Bayliss LE, et al. — The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study.. The Lancet, 2017. DOI: 10.1016/S0140-6736(17)30059-4.

9. In a three-arm randomized trial of 204 people with MRI-confirmed gluteal tendinopathy, an eight-week physiotherapist-led education and exercise programme produced success on global rating of change in 51/66 participants at 8 weeks versus 38/65 for a single corticosteroid injection and 20/68 for wait-and-see. Education plus exercise beat the injection at 8 weeks (risk difference 19.9%) and still beat it at 52 weeks (20.4%).

   Mellor R, et al. — Education plus exercise versus corticosteroid injection use versus a wait and see approach on global outcome and pain from gluteal tendinopathy: prospective, single blinded, randomised clinical trial.. BMJ, 2018. DOI: 10.1136/bmj.k1662.